2篇
您的检索式：作者名="Anjing Liang"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Collagen type Ⅱ suppresses articular chondrocyte hypertrophy and osteoarthritis progression by promoting integrin β1-SMAD1 interaction显示文摘Hypertrophic differentiation is not only the terminal process of endochondral ossification in the growth plate but is also an important pathological change in osteoarthritic cartilage.Collagen type II(COL2A1)was previously considered to be only a structural component of the cartilage matrix,but recently,it has been revealed to be an extracellular signaling molecule that can significantly suppress chondrocyte hypertrophy.However,the mechanisms by which COL2A1 regulates hypertrophic differentiation remain unclear.In our study,a Col2a1 p.Gly1170Ser mutant mouse model was constructed,and Col2a1 loss was demonstrated in homozygotes.Loss of Col2a1 was found to accelerate chondrocyte hypertrophy through the bone morphogenetic protein(BMP)-SMAD1 pathway.Upon interacting with COL2A1,integrinβ1(ITGB1),the major receptor for COL2A1,competed with BMP receptors for binding to SMAD1 and then inhibited SMAD1 activation and nuclear import.COL2A1 could also activate ITGB1-induced ERK1/2 phosphorylation and,through ERK1/2-SMAD1 interaction,it further repressed SMAD1 activation,thus inhibiting BMP-SMAD1-mediated chondrocyte hypertrophy.Moreover,COL2A1 expression was downregulated,while chondrocyte hypertrophic markers and BMP-SMAD1 signaling activity were upregulated in degenerative human articular cartilage.Our study reveals novel mechanisms for the inhibition of chondrocyte hypertrophy by COL2A1 and suggests that the degradation and decrease in COL2A1 might initiate and promote osteoarthritis progression. | Chengjie Lian Xudong Wang Xianjian Qiu Zizhao Wu Bo Gao Lei Liu Guoyan Liang Hang Zhou Xiaoming Yang Yan Peng Anjing Liang Caixia Xu Dongsheng Huang Peiqiang Su | 2019 | Bone Research2019，7，1： | 17 |
| 2 | 定量分析乳腺癌术后化疗前外周血多药耐药基因的检测及其临床意义的研究(英文)显示文摘Objective: To explore expressions of multidrug resistance gene (MDR) product P170 and peripheral blood MDR1 mRNA in breast cancer tissue and their clinical significances. Methods: Fluorescent quantitative RT-PCR and immunohis-tochemistry were used to detect peripheral blood MDR1 mRNA before chemotherapy in breast cancer tissue samples from 32 cases with P170 positive (trial group) and 11 cases with P170 negative (control group). Results: There were 14 cases (43.75%) peripheral blood MDR1 mRNA positive and 18 cases (56.25%) negative in 32 cases P170 positive breast cancer pa-tients, while there were 6 cases (54.55%) peripheral blood MDR1 mRNA positive and 5 cases (45.45%) negative in 11 cases P170 negative breast cancer patients; there wasn't a significance difference with peripheral blood MDR1 mRNA express rate in P170 positive (43.75%) group and P170 negative (54.55%) group (χ2 = 0.383, P > 0.05). There were 12 cases (37.50%) Her-2 positive and 20 cases (62.50%) negative in P170 positive group; there were 2 cases (18.18%) Her-2 positive and 9 cases (81.82%) negative in P170 negative group; there wasn't a significance difference with Her-2 positive rate in P170 posi-tive group (37.50%) and P170 negative (18.18%) group (χ2 = 1.391, P > 0.05). There were 13 cases (40.63%) ER positive and 19 cases (59.37%) negative in P170 positive group; there were 7 cases (63.64%) ER positive and 4 cases (36.36%) negative in P170 negative group; there wasn't a significance difference with ER positive rate in P170 positive group (40.63%) and P170 negative (63.64) group (χ2 = 1.742, P > 0.05). There were 20 cases (62.50%) PR positive and 12 cases (37.50%) negative in P170 positive group; there were 4 cases (36.36%) PR positive and 7 cases (63.64%) negative in P170 negative group; there wasn't a significance difference with PR positive rate in P170 positive group (62.50%) and P170 negative (36.36%) group (χ2 = 2.267, P > 0.05). There were 9 cases (28.12%) with lymphaden metastasis and 23 cases (71.88%) without lymphaden metastasis in P170 positive group; there were 5 cases (45.45%) with lymphaden metastasis and 6 cases (54.55%) without lymphaden metastasis in P170 negative group; there wasn't a significance difference with lymphaden metastasis rate in P170 positive group (28.12%) and P170 negative (45.45%) group (χ2 = 1.120, P > 0.05). Conclusion: 1) There were possibly MDR expressing infrequently in carcinoma tissue and peripheral blood before chemotherapy. 2) FQ-RT-PCR for detecting of periph-eral blood MDR1 mRNA is special, sensitive and reliable. It can be used as new molecular biology diagnostic maker dynamic detecting peripheral blood MDR1 mRNA for regulating chemotherapy proposal and elevating chemotherapy effect. | Xinmei Wang Liang Li Qjng Cuix Muxin Wang Yu Ding Tongfu Jia Jianzhao Li Ningning Feng Anjing Zuo Yanchang Feng | 2008 | The Chinese-German Journal of Clinical Oncology2008，7，11： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员